Literature DB >> 19498040

Stabilizers of the Max homodimer identified in virtual ligand screening inhibit Myc function.

Hao Jiang1, Kristen E Bower, Albert E Beuscher, Bin Zhou, Andrey A Bobkov, Arthur J Olson, Peter K Vogt.   

Abstract

Many human cancers show constitutive or amplified expression of the transcriptional regulator and oncoprotein Myc, making Myc a potential target for therapeutic intervention. Here we report the down-regulation of Myc activity by reducing the availability of Max, the essential dimerization partner of Myc. Max is expressed constitutively and can form unstable homodimers. We have isolated stabilizers of the Max homodimer by applying virtual ligand screening (VLS) to identify specific binding pockets for small molecule interactors. Candidate compounds found by VLS were screened by fluorescence resonance energy transfer, and from these screens emerged a potent, specific stabilizer of the Max homodimer. In vitro binding assays demonstrated that the stabilizer enhances the formation of the Max-Max homodimer and interferes with the heterodimerization of Myc and Max in a dose-dependent manner. Furthermore, this compound interferes with Myc-induced oncogenic transformation, Myc-dependent cell growth, and Myc-mediated transcriptional activation. The Max-Max stabilizer can be considered a lead compound for the development of inhibitors of the Myc network.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19498040      PMCID: PMC2730382          DOI: 10.1124/mol.109.054858

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  37 in total

Review 1.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.

Authors:  C A Lipinski; F Lombardo; B W Dominy; P J Feeney
Journal:  Adv Drug Deliv Rev       Date:  2001-03-01       Impact factor: 15.470

Review 2.  Function and regulation of the transcription factors of the Myc/Max/Mad network.

Authors:  B Lüscher
Journal:  Gene       Date:  2001-10-17       Impact factor: 3.688

3.  Efficient docking of peptides to proteins without prior knowledge of the binding site.

Authors:  Csaba Hetényi; David van der Spoel
Journal:  Protein Sci       Date:  2002-07       Impact factor: 6.725

4.  Max protein expression is associated with survival of children with lymphoblastic lymphoma.

Authors:  Y Yuza; M Kawakami; K Takagi; Y Yamazaki; M Urashima
Journal:  Pediatr Int       Date:  1999-12       Impact factor: 1.524

5.  Molecular properties that influence the oral bioavailability of drug candidates.

Authors:  Daniel F Veber; Stephen R Johnson; Hung-Yuan Cheng; Brian R Smith; Keith W Ward; Kenneth D Kopple
Journal:  J Med Chem       Date:  2002-06-06       Impact factor: 7.446

6.  Structure, function, and dynamics of the dimerization and DNA-binding domain of oncogenic transcription factor v-Myc.

Authors:  W Fieber; M L Schneider; T Matt; B Kräutler; R Konrat; K Bister
Journal:  J Mol Biol       Date:  2001-04-13       Impact factor: 5.469

7.  C-myc gene expression alone is sufficient to confer resistance to antiestrogen in human breast cancer cells.

Authors:  Marcello Venditti; Barbara Iwasiow; F William Orr; Robert P C Shiu
Journal:  Int J Cancer       Date:  2002-05-01       Impact factor: 7.396

Review 8.  Contributions of Myc to tumorigenesis.

Authors:  Werner Lutz; Javier Leon; Martin Eilers
Journal:  Biochim Biophys Acta       Date:  2002-03-14

9.  Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts.

Authors:  Thorsten Berg; Steven B Cohen; Joel Desharnais; Corinna Sonderegger; Daniel J Maslyar; Joel Goldberg; Dale L Boger; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

10.  Structural rationale for the coupled binding and unfolding of the c-Myc oncoprotein by small molecules.

Authors:  Ariele Viacava Follis; Dalia I Hammoudeh; Huabo Wang; Edward V Prochownik; Steven J Metallo
Journal:  Chem Biol       Date:  2008-11-24
View more
  22 in total

Review 1.  Transcription Factor Inhibition: Lessons Learned and Emerging Targets.

Authors:  Andrew Chen; Angela N Koehler
Journal:  Trends Mol Med       Date:  2020-02-15       Impact factor: 11.951

Review 2.  Small-molecule inhibitors of the Myc oncoprotein.

Authors:  Steven Fletcher; Edward V Prochownik
Journal:  Biochim Biophys Acta       Date:  2014-03-19

3.  Functional genomics identifies therapeutic targets for MYC-driven cancer.

Authors:  Masafumi Toyoshima; Heather L Howie; Maki Imakura; Ryan M Walsh; James E Annis; Aaron N Chang; Jason Frazier; B Nelson Chau; Andrey Loboda; Peter S Linsley; Michele A Cleary; Julie R Park; Carla Grandori
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-23       Impact factor: 11.205

Review 4.  Intrinsically disordered proteins are potential drug targets.

Authors:  Steven J Metallo
Journal:  Curr Opin Chem Biol       Date:  2010-07-02       Impact factor: 8.822

Review 5.  Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases.

Authors:  Vladimir N Uversky; Vrushank Davé; Lilia M Iakoucheva; Prerna Malaney; Steven J Metallo; Ravi Ramesh Pathak; Andreas C Joerger
Journal:  Chem Rev       Date:  2014-05-15       Impact factor: 60.622

6.  The non-enzymatic RAS effector RASSF7 inhibits oncogenic c-Myc function.

Authors:  Anbarasu Kumaraswamy; Anitha Mamidi; Pavitra Desai; Ananthi Sivagnanam; Lakshmi Revathi Perumalsamy; Chandrasekaran Ramakrishnan; Michael Gromiha; Krishnaraj Rajalingam; Sundarasamy Mahalingam
Journal:  J Biol Chem       Date:  2018-08-23       Impact factor: 5.157

7.  MicroRNA-based screens for synthetic lethal interactions with c-Myc.

Authors:  Youjun Li; Yahui Zhu; Edward V Prochownik
Journal:  RNA Dis       Date:  2016-05-30

8.  Virtual Screening with AutoDock: Theory and Practice.

Authors:  Sandro Cosconati; Stefano Forli; Alex L Perryman; Rodney Harris; David S Goodsell; Arthur J Olson
Journal:  Expert Opin Drug Discov       Date:  2010-06-01       Impact factor: 6.098

9.  Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy.

Authors:  Huiying Han; Atul D Jain; Mihai I Truica; Javier Izquierdo-Ferrer; Jonathan F Anker; Barbara Lysy; Vinay Sagar; Yi Luan; Zachary R Chalmers; Kenji Unno; Hanlin Mok; Rajita Vatapalli; Young A Yoo; Yara Rodriguez; Irawati Kandela; J Brandon Parker; Debabrata Chakravarti; Rama K Mishra; Gary E Schiltz; Sarki A Abdulkadir
Journal:  Cancer Cell       Date:  2019-10-31       Impact factor: 31.743

10.  Computational protein-ligand docking and virtual drug screening with the AutoDock suite.

Authors:  Stefano Forli; Ruth Huey; Michael E Pique; Michel F Sanner; David S Goodsell; Arthur J Olson
Journal:  Nat Protoc       Date:  2016-04-14       Impact factor: 13.491

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.